tbuckley/cabot-search huggingface dataset:
SAT0377 Drug Survival of Tumor Necrosis Factor-α Inhibitors in Patients with Ankylosing Spondylitis in Korea
Authors: H. Jeong, H. Kim, J.-M. Oh, J. Kim, J. Lee, E.-M. Koh, H.-S. Cha
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Studies about factors for drug survival for patients with AS have not sufficient as compared with RA patients and only a few studies are available for the Asian population. <h3>Objectives</h3> To evaluate drug survival of the tumor necrosis factor-α inhibitors (TNFi) and risk factors for the drug discontinuation in patients with ankylosing spondylitis (AS). <h3>Methods</h3> We retrospectively evaluated 487 AS patients at a single tertiary hospital. Among the TNFi users, drug survival and risk factors of TNFi discontinuation were investigated. <h3>Results</h3> Among 487 patients, 128 AS patients were treated with at least one TNFi. Patients who were treated with TNFi were younger at disease onset, had more peripheral manifestations, and had higher level of acute phase reactants and BMI than those of TNFi non-users at baseline. Of 128 patients, 28 (21.9%) patients discontinued first TNFi therapy during the follow-up period of 65.1 ± 27.9 months. In the multivariable analysis, female (HR 6.08, 95% CI 2.27–16.27, p=0.003), hip involvement (HR 2.52, 95% CI 1.08–5.87, p=0.033) and a high CRP (HR 1.10, 95% CI 1.00–1.21, p=0.044) were risk factors for drug discontinuation. Etanercept showed better survival rate than infliximab. The main reason for discontinuation of TNFi was inefficacy. <h3>Conclusions</h3> About one fifth of patients with AS discontinued their first TNFi. Female sex, hip involvement, CRP, and the type of TNFi were associated with TNFi discontinuation. <h3>Disclosure of Interest</h3> None declared
P0146 : Oral, once-daily, cenicriviroc leads to rapid and potent CCR2 and CCR5 blockade in subjects with advanced liver disease, similar to effects seen in healthy volunteers and HIV-1 infected subjects
Authors: N.S. Utay, M. Gottwald, W. Chang, M.S. Willett, E. Lefebvre
Journal: Journal of Hepatology (2015)
KIT Induced Myeloproliferative Disease Is Dependent on PI3Kinase and SHP2 Phosphatase: Identification of SHP2 As a Druggable Target for Treating MPD and AML
Authors: Peilin Ma, Raghuveer Mali, Li-Fan Zeng, Holly Martin, Baskar Ramdas, Yantao He, Emily Sims, Joydeep Ghosh, Sarah C Nabinger, Shuo Li, Veerendra Munugalavadla, Anindya Chatterjee, George Sandusky, Andrew Craig, Kevin D. Bunting, Gen-Sheng Feng, Rebecca J. Chan, Zhong-Yin Zhang, Reuben Kapur
Journal: Blood (2011)
Extracellular ADP facilitates monocyte recruitment in bacterial infection via ERK signaling
Authors: Xiaoyu Zhang, Juliang Qin, Junyan Zou, Zhangsheng Lv, Binghe Tan, Jueping Shi, Yihan Zhao, Hua Ren, Mingyao Liu, Min Qian, Bing Du
Journal: Cellular and Molecular Immunology (2016)
Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC)
Authors: S.J.L. Mesnage, A. Auguste, C. Genestie, A. Dunant, E. Pain, F. Drusch, S. Gouy, P. Morice, E. Bentivegna, C. Lhomme, P. Pautier, J. Michels, A. Le Formal, B. Cheaib, J. Adam, A.F. Leary
Journal: Annals of Oncology (2016)
Fragmentation of Care—The Untold Story
Authors: Christopher A. Wybourn, April E. Mendoza, Andre R. Campbell
Journal: JAMA Surgery (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Novel extracellular and nuclear caspase-1 and inflammasomes propagate inflammation and regulate gene expression: a comprehensive database mining study
Authors: Luqiao Wang, Hangfei Fu, Gayani Nanayakkara, Yafeng Li, Ying Shao, Candice Johnson, Jiali Cheng, William Y. Yang, Fan Yang, Muriel Lavallee, Yanjie Xu, Xiaoshu Cheng, Hang Xi, Jonathan Yi, Jun Yu, Eric T. Choi, Hong Wang, Xiaofeng Yang
Journal: Journal of Hematology & Oncology (2016)

Caspase-1 is present in the cytosol as an inactive zymogen and requires the protein complexes named "inflammasomes" for proteolytic activation. However, it remains unclear whether the proteolytic activity of caspase-1 is confined only to the cytosol where inflammasomes are assembled to convert inactive pro-caspase-1 to active caspase-1. We conducted meticulous data analysis methods on proteomic, protein interaction, protein intracellular localization, and gene expressions of 114 experimentally identified caspase-1 substrates and 38 caspase-1 interaction proteins in normal physiological conditions and in various pathologies. We made the following important findings: (1) Caspase-1 substrates and interaction proteins are localized in various intracellular organelles including nucleus and secreted extracellularly; (2) Caspase-1 may get activated in situ in the nucleus in response to intra-nuclear danger signals; (3) Caspase-1 cleaves its substrates in exocytotic secretory pathways including exosomes to propagate inflammation to neighboring and remote cells; (4) Most of caspase-1 substrates are upregulated in coronary artery disease regardless of their subcellular localization but the majority of metabolic diseases cause no significant expression changes in caspase-1 nuclear substrates; and (5) In coronary artery disease, majority of upregulated caspase-1 extracellular substrate-related pathways are involved in induction of inflammation; and in contrast, upregulated caspase-1 nuclear substrate-related pathways are more involved in regulating cell death and chromatin regulation. Our identification of novel caspase-1 trafficking sites, nuclear and extracellular inflammasomes, and extracellular caspase-1-based inflammation propagation model provides a list of targets for the future development of new therapeutics to treat cardiovascular diseases, inflammatory diseases, and inflammatory cancers.
AB0091 Hypoxia Induce Slug Expression via JAK/STAT3 Pathway in Rheumatoid Arthritis Fibroblast-like Synoviocytes
Authors: H. Kim, H. Jeong, J. Lee, H.-S. Cha, E.-M. Koh, J.K. Ahn
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Accumulating evidence implicates hypoxia in the pathogenesis of rheumatoid arthritis (RA). The effect of hypoxia on the expression of Slug, a transcriptional repressor that impairs apoptosis of RA fibroblast-like synoviocytes (FLS), remains unknown. <h3>Objectives</h3> The aim of this study is to investigate the role of hypoxia in the expression of Slug in RA FLS and to delineate the signaling pathway involved in the process. <h3>Methods</h3> After RA FLS were exposed to hypoxia, expression of HIF1-a and phosphorylation of ERK, JNK, and STAT3 were analyzed by Western blot. The experiment was repeated with RA FLS pretreated with WP1066, an inhibitor of the JAK/STAT pathway. RT-PCR was performed to measure HIF-1a mRNA and Slug mRNA expressions in RA FLS under hypoxia. RA FLS was transfected with HIF-1a cDNA to investigate the effect of overexpression of HIF-a on Slug expression. Immunohistochemistry was used to assess the presence HIF-1a and Slug in RA synovial tissue. Microarray analysis was performed to investigate the change in Slug gene expression when FLS were exposed to hypoxia. Finally, the effect of TNF-α on Slug and HIF-1α expressions under normoxic conditions was assessed in RA FLS by Western blot. <h3>Results</h3> Hypoxia induced the expression of HIF-1a and phosphorylation of STAT3, but not JNK and ERK was increased in RA FLS. Pre-treatment of RA FLS with WP1066 before exposure to hypoxia inhibited the expression of p-STAT and HIF-1a. Hypoxic conditions induced Slug mRNA expression from RA FLS, and similarly, overexpression of HIF-1a in RA FLS reproduced enhanced Slug expression. Microarray analysis revealed a significantly up-regulated Slug expression. Immunohistochemical staining showed that HIF-1a and Slug were co-localized in the lining area of RA synovium. Stimulation of FLS with TNF-α alone without hypoxia resulted in increased expression of Slug HIF-1a and Slug. <h3>Conclusions</h3> Our study demonstrates that HIF-1a expression from RA FLS induced by hypoxia or TNF-a alone is mediated through JAK/STAT3 signaling pathway, which ultimately leads to the expression of Slug. Hypoxia-driven pathway of Slug expression may become a novel treatment target in RA. <h3>Disclosure of Interest</h3> None declared
Inhibitory Effects of Monocytes on CD4+Foxp3+ T Cell Expansion In Patients with Immune Thrombocytopenia (ITP)
Authors: Hui Zhong, Weili Bao, Xiaojuan Li, Wu He, Nayla Boulad, Zeeshan Hafeez, James B. Bussel, Karina Yazdanbakhsh
Journal: Blood (2010)
Reversal of T Cell Exhaustion in Pre-Treatment Marrow T Cells Is Associated with Effective Graft-Versus-Leukemia Responses to Donor Lymphocyte Infusion
Authors: Pavan Bachireddy, Ursula Hainz, Michael Rooney, Olga Pozdnyakova, Julie Aldridge, W. Nicholas Haining, Natalie R. Goldstein, Christine M Canning, Robert J. Soiffer, Jerome Ritz, Nir Hacohen, Haesook T Kim, Edwin P Alyea, Catherine J Wu
Journal: Blood (2012)
PTH-048 Towards Understanding Psychological Distress in Inflammatory Bowel Disease: A Qualitative Study of Patients and Healthcare Professionals
Authors: A Fischer, P Irving, R Moss-Morris, LD Hughes
Journal: Gut (2016)

<h3>Introduction</h3> Inflammatory Bowel Diseases (IBD) are chronic inflammatory autoimmune conditions resulting in sickness, diarrhoea, weight loss, abdominal pain and fatigue. Depression and anxiety are high at 21% and 41% respectively resulting in further reduced quality of life. However, most IBD services do not have access to psychological support or dedicated resources for distress. This study aimed to identify modifiable factors associated with the occurrence of distress in IBD to inform a guided self-management intervention. <h3>Methods</h3> Semi-structured interviews were carried out with 29 people with IBD (pwIBD) and twelve healthcare professionals. Interviews were audio-recorded and transcribed verbatim. Data were analysed using thematic analysis with elements of grounded theory. <h3>Results</h3> A model of factors identified by pwIBD contributing to distress was developed. Themes included; symptoms which can be embarrassing and uncontrollable during flares; unpredictability and progression of IBD, creating uncertainty for the future; social factors including lack of understanding and the negative impact on social relationships; navigating the healthcare system; medical procedures which can be unpleasant and invasive. Some themes were also recognised as being potential buffers to distress such as having good social support and healthcare staff. Healthcare professionals acknowledged their role in holistic care but cited a lack of knowledge and resources to adequately promote psychological support. <h3>Conclusion</h3> PwIBD identified areas acting as potential promoters and buffers to distress in IBD which were mostly supported by healthcare professionals. The results were used to inform the content of a self-management intervention targeting psychological distress. Further we seek to develop guidelines for the successful introduction of the intervention into the NHS standard care. <h3>Disclosure of Interest</h3> None Declared
Sunitinib in Relapsed or Refractory Diffuse Large B Cell Lymphoma: Results of a Phase II Multi-Center Study of the NCIC Clinical Trials Group.
Authors: Rena Buckstein, John Kuruvilla, Neil Chua, Christina Lee, David A Macdonald, Abdulwahab J. Al-Tourah, Alison Foo, Wendy Walsh, S. Percy Ivy, Michael Crump, Elizabeth Eisenhauer
Journal: Blood (2009)
The Outcome of T-Cell Lymphoma Patients Failing First-Line Treatment: Results of a Population Based-Study From the Modena Cancer Registry
Authors: Irene Biasoli, Marina Cesaretti, Stefano Luminari, Monica Bellei, Alessandra Dondi, Emanuela Anna Pesce, Stefania Badiali, Micol Quaresima, Maria Angela Sirotti, Massimo Federico
Journal: Blood (2012)
CD19 Targeting of Lymphoid Malignancies by Novel Fc-Domain Engineered Monoclonal Antibody.
Authors: Farrukh Awan, Rosa Lapalombella, Rossana Trotta, Jonathan P Butchar, Bo Yu, Don Benson, Carolyn Cheney, Xiaokui Mo, Amy Lehman, Jeffrey Alan Jones, Joseph M Flynn, David Jarjoura, Robert A. Baiocchi, John Desjarlais, Susheela Tridandapani, Michael A. Caligiuri, Natarajan Muthusamy, John C. Byrd
Journal: Blood (2009)
PWE-009 Current Practice and Clinicians’ Perception of Medication Non-Adherence in Patients with IBD
Authors: S Boughdady, A Soobraty, C Selinger
Journal: Gut (2016)

<h3>Introduction</h3> Non-adherence to IBD maintenance medication occurs in 30–45% with mesalazine (5 ASA), 15–20% with immunomodulators (IMM), 5–10% with biologics (BIOL); yet clinicians struggle to detect and address non-adherence. Little is known how clinicians perceive the issue of non-adherence and how they address adherence questions (screening and interventions). This survey ascertains perceptions and describes current practice. <h3>Methods</h3> Consultant gastroenterologists, trainees and IBD specialist nurses from the UK were invited to a web based survey. Data were collected on clinician demographics, patient volume and level of interest in IBD. We assessed perception of non-adherence by overall impression and asked respondents to estimate non-adherence for 5 ASA, IMM and BIOL therapy. Current practice assessment included use of screening tools and interventions to improve adherence. <h3>Results</h3> Of 98 respondents (53.1% were female, 53.1% &lt; 44 years) 51 were consultants, 17 trainees, 28 IBD specialist nurses and 2 other. Half of respondents had ≥15 years’ experience. Medical staff were classed as general gastroenterologists (43%), having IBD interest (32%) and IBD experts (25%). Non-adherence was seen as an infrequent problem by 57%. Older respondents saw non-adherence as an infrequent problem more often (p = 0.006). The level of non-adherence was estimated as lower than evidence suggests by 31% of respondents for 5 ASA, 28% for IMM and 23% for BIOL. Respondents reporting non-adherence to be a frequent problem were more likely to report adherence levels in line with established evidence (5 ASA p &lt; 0.001; IMM p = 0.012; BIOL p = 0.015). Gender, age, years of practice, level of interest, professional status (consultant vs trainee vs nurse), and patient volume did not influence the likelihood of estimating adherence levels in line with the evidence. Respondents stated forgetfulness, beliefs about necessity of medication and not immediately apparent benefits as the main reasons for non-adherence. While 80% regarded screening as important only 25% screen regularly. Only 40% used validated assessment tools. Patient counselling on benefits and risks of medication was the most commonly used intervention. <h3>Conclusion</h3> Clinicians treating IBD patients frequently underestimate non-adherence and use of validated screening tools is infrequent. This phenomenon occurs across grades and professions. Most respondents identified the main factors associated with non-adherence in line with evidence and counselled patients accordingly. Professional education should focus more on non-adherence practice to avoid adverse treatment outcomes associated with non-adherence. <h3>Disclosure of Interest</h3> S. Boughdady: None Declared, A. Soobraty: None Declared, C. Selinger Grant/research support from: Abbie, Warner Chilcott, Consultant for: Abbie, Warner Chilcott, Dr Falk, Takeda, Speaker bureau with: Abbie, Warner Chilcott, MSD, Takeda
Clinical commissioning groups will be rated on sepsis care
Authors: Jacqui Wise
Journal: BMJ (2016)

Different areas of the country will be rated on how well they identify and treat sepsis, NHS England has announced.

Bruce Keogh, NHS England medical director, announced that a sepsis specific indicator will be included in the clinical commissioning group information and assessment framework alongside metrics on cancer, dementia, diabetes, mental health, learning disabilities, and maternity care.

Keogh made the announcement at the launch of a new public awareness campaign, led by Public Health England and the UK Sepsis Trust, which aims to help parents and carers of young children to recognise the symptoms of sepsis and to know when to seek urgent help.

A report into sepsis by the National …
Genoidentical Donor Versus A, B, Cw, DR, DQ, HLA Allelic-Matched Unrelated Donor for Stem Cell Transplantation in Patients with Standard Risk Haematological Malignancy.
Authors: Ibrahim Yakoub-Agha, Jean-Michel Boiron, Mauricette Michallet, Noel Milpied, Jean-Henri Bourhis, Jean-Yves Cahn, Agnes Buzyn, Nicole Gratecos, Helene Esperou, Jean-Paul Vernant, Colette Raffoux, Jean-Louis Golmard, Jean-Pierre Jouet, Mathieu Kuentz
Journal: Blood (2004)
Predicting sport and occupational lower extremity injury risk through movement quality screening: a systematic review
Authors: Jackie L Whittaker, Nadine Booysen, Sarah de la Motte, Liz Dennett, Cara L Lewis, Dave Wilson, Carly McKay, Martin Warner, Darin Padua, Carolyn A Emery, Maria Stokes
Journal: British Journal of Sports Medicine (2016)

Background Identification of risk factors for lower extremity (LE) injury in sport and military/first-responder occupations is required to inform injury prevention strategies. Objective To determine if poor movement quality is associated with LE injury in sport and military/first-responder occupations. Materials and methods 5 electronic databases were systematically searched. Studies selected included original data; analytic design; movement quality outcome (qualitative rating of functional compensation, asymmetry, impairment or efficiency of movement control); LE injury sustained with sport or military/first-responder occupation. The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines were followed. 2 independent authors assessed the quality (Downs and Black (DB) criteria) and level of evidence (Oxford Centre of Evidence-Based Medicine model). Results Of 4361 potential studies, 17 were included. The majority were low-quality cohort studies (level 4 evidence). Median DB score was 11/33 (range 3–15). Heterogeneity in methodology and injury definition precluded meta-analyses. The Functional Movement Screen was the most common outcome investigated (15/17 studies). 4 studies considered inter-relationships between risk factors, 7 reported diagnostic accuracy and none tested an intervention programme targeting individuals identified as high risk. There is inconsistent evidence that poor movement quality is associated with increased risk of LE injury in sport and military/first-responder occupations. Conclusions Future research should focus on high-quality cohort studies to identify the most relevant movement quality outcomes for predicting injury risk followed by developing and evaluating preparticipation screening and LE injury prevention programmes through high-quality randomised controlled trials targeting individuals at greater risk of injury based on screening tests with validated test properties.
Comment on “Review of patient registries in dermatology”
Authors: Jeffrey Zweegers, Inge M. Bronckers, Juul M.P.A. van den Reek, Maartje J. van Geel, Peter C.M. van de Kerkhof, Marieke M.B. Seyger, Elke M.G.J. de Jong
Journal: Journal of the American Academy of Dermatology (2016)
Endomicroscopie confocale guidée par écho-endoscopie des masses solides du pancréas
Journal: Endoscopy (2016)

Le diagnostic du type d’une tumeur solide du pancréas par ponction sous échoendoscopie (EE) reste indéterminé dans 8 – 25 % des cas. La valeur prédictive négative d’une ponction d’adénocarcinome est de 60 – 70 %. En cas de ponction négative, on peut la répéter ou proposer une biopsie chirurgicale qui est invasive au niveau du pancréas. L’endomicroscopie confocale (EC) fournit une analyse histologique in vivo en temps réel. Initialement développée pour l’étude de la muqueuse du tube digestif, elle a été étendue aux voies biliaires puis aux lésions pancréatiques. Le but de cette étude “CONTACT” était d’établir un atlas d’images de masses pancréatiques et de valider leur valeur diagnostique.
SP0195 Osteoporosis and Cardiovascular Disease
Authors: W.F. Lems
Journal: Annals of the Rheumatic Diseases (2016)

Both osteoporotic fractures and cardiovascular events can be devastating events, which are more commonly in the elderly. This could be related to some risk factors that play a role in the pathogenesis of both events: postmenopausal estrogen deficiency, smoking, immobility and low-grade inflammation. A systematic review on the association of cardiovascular diseases and osteoporosis in the general population will be mentioned. The relationship between osteoporotic fractures and cardiovascular events could be even stronger in patients with systemic inflammatory diseases such as RA or AS. Finally, it will be discussed whether in patients with a recent cardiovascular event, it is useful to screen for underlying osteoporosis, and whether in patients with a recent fracture, cardiovascular risk factors should be determined. <h3>Disclosure of Interest</h3> None declared
Endocrine Sequelae and Metabolic Syndrome in Adult Long-Term Survivors of Childhood Acute Myeloid Leukemia
Authors: Karin Blijdorp, Marjolein van Waas, Aart-Jan van der Lely, Rob Pieters, Marry M. van den Heuvel, Sebastian J.C.M.M. Neggers
Journal: Blood (2012)